How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/extensive-stage-primary-small-cell-carcinoma-of-lung.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Extensive stage primary small cell carcinoma of lung — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Extensive stage primary small cell carcinoma of lung (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Extensive stage primary small cell carcinoma of lung, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Imfinzi	durvalumab	AstraZeneca	Programmed Death Ligand-1 Blocker [EPC]	Programmed cell death 1 ligand 1	2017-01-01
Tecentriq	atezolizumab	Roche	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed cell death 1 ligand 1	2016-01-01
Imfinzi	Imfinzi	University Medical Center Groningen		Programmed cell death 1 ligand 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 1 drug in Extensive stage primary small cell carcinoma of lung
Roche · 1 drug in Extensive stage primary small cell carcinoma of lung
University Medical Center Groningen · 1 drug in Extensive stage primary small cell carcinoma of lung

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Extensive stage primary small cell carcinoma of lung:

Cite this brief

Drug Landscape (2026). Extensive stage primary small cell carcinoma of lung — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/extensive-stage-primary-small-cell-carcinoma-of-lung. Accessed 2026-06-10.

Extensive stage primary small cell carcinoma of lung full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing